ArticleOncogene2001
Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells.
Article in Oncogene, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 62 citations in OpenAlex.
- GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment.Cell metabolism · 2022Article
- Investigation of the therapeutic effect of 5-aminolevulinic acid based photodynamic therapy on hepatocellular carcinoma.Lasers in medical science · 2022Article
- Evaluation of ATAD2 as a Potential Target in Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2021Article
- Article
- Protein kinase C inhibitors override ZEB1-induced chemoresistance in HCC.Cell death & disease · 2019Article
- Activity of IL-12/15/18 primed natural killer cells against hepatocellular carcinoma.Hepatology international · 2019Article
- Aberrant expression of alternative isoforms of transcription factors in hepatocellular carcinoma.World journal of hepatology · 2018Review
- Transcriptional deregulation underlying the pathogenesis of small cell lung cancer.Translational lung cancer research · 2018Review
- Bidirectional transcription of Linc00441 and RB1 via H3K27 modification-dependent way promotes hepatocellular carcinoma.Cell death & disease · 2017Article
- Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation.PloS one · 2017Article
- The p53R172H mutant does not enhance hepatocellular carcinoma development and progression.PloS one · 2015Article
- The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations.Cancers · 2014Article
- Centrosomal AKAP350 modulates the GCellular logistics · 2013Article
- Relative expression of TAp73 and ΔNp73 isoforms.Aging · 2012Article
- Article
- Deregulation of FoxM1b leads to tumour metastasis.EMBO molecular medicine · 2011Article
- Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Quantification of SLIT-ROBO transcripts in hepatocellular carcinoma reveals two groups of genes with coordinate expression.BMC cancer · 2008Article
- P73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis.Oncogene · 2008Article
- Cleavage of the transactivation-inhibitory domain of p63 by caspases enhances apoptosis.Proceedings of the National Academy of Sciences of the United States of America · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
p53 and p73 proteins activate similar target genes and induce apoptosis and cell cycle arrest. However, p53, but not p73 is considered a tumour-suppressor gene. Unlike p53, p73 deficiency in mice does not lead to a cancer-prone phenotype, and p73 gene is not mutated in human cancers, including hepatocellular carcinoma. Here we report that normal liver cells express only DeltaN-p73 transcript forms giving rise to the synthesis of N-terminally truncated, transcriptionally inactive and dominant negative p73 proteins. In contrast, most hepatocellular carcinoma cells express TA-p73 transcript forms encoding full-length and transcriptionally active p73 proteins, in addition to DeltaN-p73. We also show that together with the acquired expression of TA-p73, the 'retinoblastoma pathway' is inactivated, and E2F1-target genes including cyclin E and p14(ARF) are activated in hepatocellular carcinoma. However, there was no full correlation between 'retinoblastoma pathway' inactivation and TA-p73 expression. Most TA-p73-expressing hepatocellular carcinoma cells have also lost p53 function either by lack of expression or missense mutations. The p73 gene, encoding only DeltaN-p73 protein, may function as a tumour promoter rather than a tumour suppressor in liver tissue. This may be one reason why p73 is not a mutation target in hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.